Clinical Trials

Contact us

Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment

See all

Newly Diagnosed Glioblastoma

A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme *not currently enrolling

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The "ACT IV" Study) *not currently enrolling

 A Phase 3 Randomized, Double Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)

A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548

Recurrent Glioblastoma

A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma *not currently enrolling

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

A Phase 0/1 Study of Combination Drug Therapy for Glioblastoma Based on Personalized Cancer Sten Cell (CSC) High-Throughput Drug Screening

ABT-414 Alone or ABT-414 Plus Temozolomide Versus Temozolomide or Lomustine for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group *not currently enrolling

A Phase 3 Randomized Controlled Double-Arm Open-Label Multi-Center Study Of VB-111 Combines With Bevacizumab vs. Bevacizumab Monotherapy In Patients With Recurrent Glioblastoma

Metastatic Brain Tumors

A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors